Immunocore Holdings Plc - Company Profile
Powered by
All the data and insights you need on Immunocore Holdings Plc in one report.
- Save hours of research time and resources with
our up-to-date Immunocore Holdings Plc Strategy Report
- Understand Immunocore Holdings Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Immunocore Holdings Plc (Immunocore) is a biotechnology company that- focuses on the development of immunotherapeutic drugs for the treatment of cancer, infectious diseases, and autoimmune diseases. The company develops its drugs using proprietary T cell receptor (TCR) technology. Its products under development include IMC-C103C, IMC-F106C, IMC-I109V, IMC-M113V and IMCgp100. The company works in collaboration with various pharmaceutical companies, to develop its product candidates for the treatment of metastatic cutaneous melanoma; cancer; and other indications. It has presence in the UK, the US, Australia, New Zealand and Asia, Europe. Immunocore is headquartered in Oxfordshire, the UK.
Immunocore Holdings Plc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
KIMMTRAK (tebentafusp-tebn) | Immunocore |
Pipeline | ImmTAC |
Oncology: | ImmTAX |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
Competitor Comparison
Key Parameters | Immunocore Holdings Plc | Gilead Sciences Inc | Regeneron Pharmaceuticals Inc | BioNTech SE | Gritstone Bio Inc |
---|---|---|---|---|---|
Headquarters | United Kingdom | United States of America | United States of America | Germany | United States of America |
City | Abingdon | Foster City | Tarrytown | Mainz | Emeryville |
State/Province | England | California | New York | Nordrhein-Westfalen | California |
No. of Employees | 497 | 18,000 | 13,450 | 6,133 | 231 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
John Bell | Chairman | Executive Board | 2015 | 70 |
Bahija Jallal, Ph.D | Director; Chief Executive Officer | Executive Board | 2019 | 61 |
Brian Di Donato | Head - Strategy; Chief Financial Officer | Senior Management | 2020 | 56 |
John Trainer | Senior Vice President; Chief Operating Officer | Senior Management | 2023 | - |
John Goll | Chief Accounting Officer; Senior Vice President | Senior Management | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer